Adam JacksonApril 3, 2023
The company's debts totaled C$136.5 million by the end of 2022.
Tag: Mydecine Innovations Group
Adam JacksonApril 3, 2023
StaffOctober 19, 2020
Mydecine Innovations Group, Inc, (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (âMydecineâ or the âCompanyâ) announced the appointment of UK-based Boustead Capital Markets LLP (âBousteadâ) to commence the dual listing process on the London Stock Exchange (âLSEâ or the âExchangeâ) for the admission of the Companyâs common shares to the Standard Segment of the Official Listâs […]
William SumnerOctober 7, 2020
Psychedelic drugs like psilocybin are a game changer in the world of mental health sciences. There is a growing body of evidence that suggests psilocybin has the potential to help treat anxiety, depression, and post-traumatic stress disorder (PTSD). As scientific interest in psilocybin grows, so too does the attention of investors; many of whom cannot […]
StaffSeptember 24, 2020
Mindleap Health, a subsidiary of Mydecine Innovations Group Inc. (OTC:MYCOF) has launched a digital health platform that combines telehealth with mood, emotion, and habit tracking. Starting with psychedelic integration, the Mindleap platform will bring mental health specialists online, enabling a new era of digital mental health and wellness. The company said that later this year […]
StaffAugust 18, 2020
Under the coverage of a Health Canada Schedule 1 Controlled Drugs and Substances Dealerâs License, Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine⢔ or the “Company”) announced that it is the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, naturally derived from whole-mushroom […]
AxisWireAugust 18, 2020Being Facilitated Under a Schedule 1 Health Canada Dealerâs License DENVER, Colorado, USA, August 18, 2020 /AxisWire/ Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine⢔ or the “Company”) is pleased to announce it is the first organization to exercise its cGMP(â) capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin, […]
StaffJuly 24, 2020
As the psychedelics and functional mushrooms industry continues to carve out its own space in today’s world, we continue to see massive talent move into the highest positions available. Similar to where cannabis was just a few years ago. Â Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) (“Mydecine” or the “Company”) announced that they […]
StaffJuly 21, 2020
Today Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) (âMydecineâ or the âCompanyâ) announced that its subsidiary Mindleap Health Inc. ( âMindleapâ ) Â signed an agreement with Brightmind (âBrightmindâ) to launch a comprehensive meditation program on Mindleapâs advanced digital health platform. Brightmind is a leading meditation app that provides customized and practical instruction by […]
AxisWireJuly 21, 2020
Vancouver – July 21, 2020 /AxisWire/ Mydecine Innovations Group Inc. (CSE: MYCO) (OTCMKTS: MYCOF) (FSE:0NF) (âMydecineâ or the âCompanyâ) is pleased to announce that its subsidiary Mindleap Health Inc. ( âMindleapâ ) has signed an agreement dated July xx, 2020Â with Brightmind (âBrightmindâ) to launch a comprehensive meditation program on Mindleapâs advanced digital health platform. […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.